A Pap test can reveal glandular cells with an unusual appearance, a finding recorded as AGC. It is not a cancer diagnosis by itself. The result prompts further evaluation based on the cell subtype, HPV status, symptoms, age, and screening history.
This guide explains the report, possible causes, follow-up tests, and details to discuss with your healthcare professional. You can use it to prepare for a focused clinical review.
How to Read the AGC Pap Test Finding
A Pap test collects cervical cells and examines them under a microscope through cervical cytology. The laboratory compares their size, shape, arrangement, and staining with expected patterns. An AGC designation identifies glandular cells that did not fit a normal category.
Those cells may come from the endocervical canal, which leads toward the uterus, or from the endometrium, the uterine lining. Endometrial cells can be expected at certain stages of the menstrual cycle, although their appearance and your clinical context still influence interpretation.
The Cell Types Included in the Report
Glandular and squamous cells grow in different parts of the cervix. Identifying the exact cell type helps your clinician choose an appropriate evaluation. A report may name endocervical cells, endometrial cells, or glandular cells without confirming the tissue source.
| Report wording | Cell focus | What it communicates |
|---|---|---|
| AGC | Glandular cells | Unusual glandular-cell features require classification and clinical review. |
| Atypical endocervical cells NOS | Endocervical cells | The cells appear atypical, but the available features do not support a more specific category. |
| Endometrial cells | Cells from the uterine lining | Menstrual timing, age, symptoms, and the cell pattern affect interpretation. |
| Atypical squamous cells | Surface squamous cells | A different cervical cell type is involved and may follow a different pathway. |
You should locate the wording beside “AGC” in your complete report. A general abbreviation can conceal a more specific classification. Bring the original document because a prior screening result or clinician note may change the next step.
Looking beneath the abbreviation helps explain why otherwise healthy cervical cells may still receive an atypical classification.
Why Glandular Cells May Appear Atypical
A sample collected during menstruation can contain endometrial cells affected by hormonal and menstrual changes. Those cells may appear different from cells seen at another point in the cycle. Timing the test relative to your cycle can therefore provide useful context.
Inflammation from infection or cervical irritation can also change endocervical-cell appearance without establishing cancer. The specimen records morphology, while your history supplies information the microscope cannot capture. You can report infections, recent procedures, symptoms, and menstrual timing during the visit.
Common Explanations Considered During Review
A clinician evaluates several categories because a single appearance can fit more than one explanation. The most relevant cause depends on the cells, specimen quality, and your clinical circumstances. Your report should be interpreted rather than translated from its abbreviation alone.
- Inflammation: Infection or irritation can alter the appearance and arrangement of endocervical cells.
- Hormonal influence: Menstrual timing and hormone levels can affect the cells present in a specimen.
- Sampling limits: A cervical sample may not contain enough material or context for a specific classification.
- Precancerous change: Some glandular abnormalities need closer examination before their significance can be determined.
- Uncertain origin: A Pap specimen may contain cells whose exact tissue source cannot be confirmed.
Symptoms provide another diagnostic clue. Bleeding between periods, after intercourse, or after menopause warrants prompt medical attention. Pelvic pain or unusual discharge may also affect your assessment, although neither symptom identifies the cause by itself.
What Atypical Glandular Cell Causes Can Include
Possible causes range from reactive changes to abnormalities that require tissue evaluation. A microscope can document the pattern, but it often cannot determine the biological reason. Your healthcare professional must connect that pattern with your symptoms and history.
You can distinguish a description from a diagnosis by noting what the report does not say. Terms such as “atypical” or “not otherwise specified” describe the appearance and limits of classification. They do not, by themselves, establish that a precancerous lesion or cancer is present.
What AGC NOS Means in the Bethesda System
The Bethesda System gives cervical cytology findings standardized names so laboratories and clinicians can communicate clearly. AGC NOS means atypical glandular cells were present, but the available features did not support a more specific Bethesda category. NOS stands for “not otherwise specified.”
This designation describes a reporting limit rather than a cancer diagnosis. The laboratory may see abnormal features without enough evidence to identify the source or narrow the category. Your clinician then evaluates the finding using the complete report and clinical context.
Why Exact Wording Guides the Evaluation
Your report may list AGC NOS, atypical endocervical cells NOS, or a more specific glandular classification. Each phrase directs attention toward a different set of possibilities. Age, symptoms, HPV testing, and prior screening can further shape the recommended pathway.
| Classification | Meaning | Practical effect |
|---|---|---|
| AGC NOS | Atypical glandular cells without a more specific category | The full report and clinical context guide evaluation. |
| Atypical endocervical cells NOS | Limited or insufficient endocervical-cell features | Evaluation may focus on the endocervical canal and related cell sources. |
| Atypical endometrial cells | Unusual cells associated with the uterine lining | Menstrual status, symptoms, age, and clinical history become especially relevant. |
| More specific glandular finding | Defined features support a narrower classification | Follow-up may be tailored to the documented cell pattern. |
You can prevent confusion by asking for the complete cytology report rather than relying on the abbreviation alone. Highlight the exact subtype and any comments from the laboratory. Your appointment becomes more focused when the original language is available.
Because HPV status changes how clinicians interpret an AGC finding, it remains a clue rather than a cancer diagnosis.
How HPV Testing Affects an AGC Evaluation
Human papillomavirus testing can help determine how closely your clinician must evaluate an abnormal cervical screening result. A positive result shows the presence of HPV, not the presence of cancer. A negative result also does not explain every possible cause of atypical glandular cells.
HPV-positive and HPV-negative results may lead to different approaches when considered with the AGC subtype. Neither result replaces the cytology report, your symptoms, or a physical examination. You should review both results together rather than focusing on either one in isolation.
What HPV Status Does Not Tell You
HPV may be present despite a normal Pap result, and an atypical finding does not establish HPV as the cause. The virus result is one piece of clinical information rather than a stand-alone answer. Your clinician must interpret it alongside the cells and your screening history.
Certain high-risk HPV results can receive more attention than low-risk results, but the meaning still depends on the screening context. A result that looks alarming in isolation may carry less significance when combined with the report and history. You can ask which HPV result was recorded and how it affects the plan.
Is an AGC Result a Diagnosis of Cervical Cancer
Finding atypical glandular cells on a Pap test does not mean that cervical cancer has been diagnosed. It identifies an abnormal cellular pattern that requires further assessment. Cervical adenocarcinoma is a cancer arising from glandular cells, but screening alone cannot confirm that diagnosis.
Precancerous glandular lesions, cervical adenocarcinoma, and abnormalities involving the endometrium are among the clinical concerns reviewed after this finding. Their inclusion explains the need for follow-up. It does not mean that your specimen contains any one of them.
How Colposcopy and Biopsy Add Evidence
Colposcopy uses magnification and light to inspect cervical tissue. During the examination, a clinician may sample areas that appear abnormal. The procedure provides visual and tissue evidence, but its findings do not predict the result in advance.
A biopsy removes tissue for examination. Endocervical sampling, sometimes called endocervical curettage, may be used in particular circumstances. Your clinician can explain why a biopsy, endocervical sampling, or another procedure fits your subtype and symptoms.
Endometrial evaluation may also be relevant when the report includes atypical endometrial cells. Bleeding after menopause, abnormal bleeding patterns, and clinical history can affect that decision. No single test applies to every person with the same laboratory wording.
What Happens After an AGC Result
Your clinician may order reflex HPV testing, repeat cervical cytology, colposcopy, or tissue sampling. The sequence depends on the exact AGC category and the information available. Age, symptoms, medical history, pregnancy status, and prior screening also influence the choice.
Reflex HPV testing may occur when the laboratory’s protocol identifies HPV testing as the next step for the reported finding. If HPV testing was not performed, your clinician may discuss whether it would add useful context. You can ask which result is already available before scheduling another test.
Preparing for the Follow-Up Decision
Your complete Pap report, HPV results, and prior screening records form the foundation of the follow-up visit. Include the date of your last cervical screening and any previous colposcopy. A written symptom list can help you explain changes that occurred before the test.
- Review the exact report: Confirm the AGC subtype and the glandular-cell source named by the laboratory.
- Record HPV status: Determine whether HPV testing occurred and note whether the result was positive or negative.
- Compare screening history: Bring prior cervical cytology, HPV, and colposcopy records.
- Document symptoms: Note bleeding patterns, pelvic pain, unusual discharge, and changes after menopause.
- Ask about timing: Confirm when the next test or examination should occur.
- Clarify each procedure: Learn whether repeat cytology, colposcopy, endocervical curettage, or biopsy would address a specific uncertainty.
You do not need to choose the procedure alone. Your role is to provide complete information and understand the purpose of each recommendation. Your clinician can connect the subtype, HPV result, symptoms, and history into one evaluation plan.
How to Prepare for a Follow-Up Appointment
Bring the original report rather than a cropped screenshot or isolated abbreviation. The full document may include a cell source, qualifier, and testing note that alter the recommended pathway. You can highlight the relevant line before the appointment.
Persistent bleeding between periods, after intercourse, or after menopause deserves timely evaluation. Pelvic pain or unusual discharge can also matter alongside an abnormal screening result. These symptoms do not prove cancer, but you should not dismiss changes from your usual pattern.
Your healthcare professional can tailor the plan to the AGC subtype, HPV status, age, and symptoms. One general classification without concerning symptoms may lead to a different route from persistent bleeding or a more specific glandular finding. Clinical assessment provides a stronger basis than an abbreviation lookup alone.
Questions You Can Ask About the Plan
You can ask which clinical uncertainty each proposed test is expected to address. It helps to know whether the next step is intended to refine risk, inspect tissue, or obtain a specimen. Written instructions make the timing easier to follow.
- Clarify the subtype: Ask what exact cell type and Bethesda category appear in your report.
- Confirm HPV results: Determine whether testing was performed and how the result changes evaluation.
- Set follow-up timing: Ask when the next cervical screening or examination should occur.
- Explain procedures: Learn why colposcopy, endocervical curettage, or biopsy may or may not be appropriate.
- Address symptoms: Discuss when abnormal bleeding, pain, or discharge needs separate evaluation.
Key Takeaways for an AGC Pap Test Result
An AGC result means unusual glandular cells were seen in a cervical cytology specimen. It is not a stand-alone cancer diagnosis. The subtype, HPV status, symptoms, age, and screening history determine the evaluation your healthcare professional may recommend.
You can prepare by bringing the complete report, relevant HPV results, prior screening records, and a timeline of symptoms. Reviewing unusual bleeding promptly is especially important. This information helps your clinician distinguish routine follow-up from a need for closer examination.
Frequently Asked Questions About AGC
What does AGC mean on a Pap test?
AGC means atypical glandular cells were seen during cervical cytology. It describes a laboratory finding about cell appearance, not a diagnosis of cancer. The exact subtype and your clinical context determine what follow-up is appropriate.
What types of atypical glandular cells may be reported?
Reports may identify AGC NOS, atypical endocervical cells NOS, or atypical endometrial cells. More specific glandular classifications may also be used when the observed features support a narrower category. NOS means “not otherwise specified.”
What causes an AGC result?
Possible causes include inflammation, hormonal changes, sampling conditions, or glandular changes that need closer examination. Cytology can describe the cells but often cannot identify the exact cause. Your symptoms, menstrual timing, and medical history help the clinician interpret the result.
Is an AGC result a diagnosis of cancer?
No. AGC by itself does not confirm cervical cancer. It identifies cells that need further clinical evaluation, which may include HPV testing, repeat cytology, colposcopy, or sampling based on your report and history.
How is AGC different from atypical squamous cells?
Glandular cells and surface squamous cells have distinct structures, making their atypical findings different categories. Because these cells arise from different cervical tissues, the findings may follow different evaluation pathways. Your report’s exact cell-type wording matters.
What happens after an AGC Pap result?
Follow-up may include HPV testing, repeat cytology, colposcopy, endocervical sampling, or biopsy. The recommended combination depends on the AGC subtype, HPV status, age, symptoms, and medical history. Your clinician can explain which option applies to you and why.
